Release Date
Geography
Language of Resource
Full Text Available
Open Access / OK to Reproduce
Peer Reviewed
Objective
To ensure optimal management of opioid use disorder (OUD), the updated 2024 CRISM National Guideline incorporates recent research, clinical insights, and input from individuals with lived experience, aiming to provide evidence-based high-standard care practices. This guideline is designed for decision-making in the general care of patients with OUD.
Findings/Key points
The recommendations suggest that buprenorphine and methadone should both be considered as first-line treatment options and slow-release oral morphine should be available and offered as a second-line option. The document includes recommended evidence-based approach for withdrawal management, complementary evidence-based interventions: psychosocial and harm reduction interventions.
A synopsis of the Guideline was published in the Canadian Medical Association Journal (November 12, 2024) or download the PDF.
